Intracellular expression of IRF9 Stat fusion protein overcomes the defective Jak-Stat signaling and inhibits HCV RNA replication

[1]  H. Te,et al.  Epidemiology of hepatitis B and C viruses: a global overview. , 2010, Clinics in liver disease.

[2]  T. Foster,et al.  Impaired antiviral activity of interferon alpha against hepatitis C virus 2a in Huh-7 cells with a defective Jak-Stat pathway , 2010, Virology Journal.

[3]  William M. Lee,et al.  Variants in interferon‐alpha pathway genes and response to pegylated interferon‐Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long‐term treatment against cirrhosis trial , 2009, Hepatology.

[4]  K. Eguchi,et al.  Predictive Value of the Phosphorylation of Signal Transducers and Activators of Transcription in the Outcome of Interferon Therapy for Chronic Hepatitis C , 2009, Intervirology.

[5]  A. Lloyd,et al.  Immunological determinants of the outcomes from primary hepatitis C infection , 2009, Cellular and Molecular Life Sciences.

[6]  Milton W. Taylor,et al.  Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. , 2008, Journal of hepatology.

[7]  Edward J Oakeley,et al.  Interferon signaling and treatment outcome in chronic hepatitis C , 2008, Proceedings of the National Academy of Sciences.

[8]  H. Yang,et al.  Associations between the human MHC and sustained virologic response in the treatment of chronic hepatitis C virus infection , 2008, Genes and Immunity.

[9]  R. Garry,et al.  Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in Hepatitis C virus replicon , 2007, Virology Journal.

[10]  M. Alter,et al.  Epidemiology of hepatitis C virus infection. , 2007, World journal of gastroenterology.

[11]  H. Wedemeyer,et al.  Treating viral hepatitis C: efficacy, side effects, and complications , 2006, Gut.

[12]  J. Dome,et al.  Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis , 2006, Oncogene.

[13]  Theodore Y Sy,et al.  Epidemiology of Hepatitis C Virus (HCV) Infection , 2006, International journal of medical sciences.

[14]  A. Aceti,et al.  Undetectable phospho‐STAT1 in peripheral blood mononuclear cells from patients with chronic hepatitis C who do not respond to interferon‐α therapy , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[15]  J. Crawford,et al.  Defective Jak-Stat activation in hepatoma cells is associated with hepatitis C viral IFN-alpha resistance. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[16]  S. Goodbourn,et al.  Activation of Interferon-Stimulated Response Element in Huh-7 Cells Replicating Hepatitis C Virus Subgenomic RNA , 2005, Intervirology.

[17]  B. Gao,et al.  Host factors and failure of interferon‐α treatment in hepatitis C virus , 2004 .

[18]  J. Pawlotsky.  The nature of interferon-α resistance in hepatitis C virus infection , 2003 .

[19]  J. Pawlotsky,et al.  Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. , 2003, Antiviral research.

[20]  C. Horvath,et al.  A Hybrid IRF9-STAT2 Protein Recapitulates Interferon-stimulated Gene Expression and Antiviral Response* , 2003, The Journal of Biological Chemistry.

[21]  A. Koromilas,et al.  PKR-Dependent Mechanisms of Gene Expression from a Subgenomic Hepatitis C Virus Clone , 2002, Journal of Virology.

[22]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[23]  M. Katze,et al.  To interfere and to anti-interfere: the interplay between hepatitis C virus and interferon. , 2002, Viral immunology.

[24]  C. Samuel,et al.  Antiviral Actions of Interferons , 2001, Clinical Microbiology Reviews.

[25]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[26]  D. R. Taylor,et al.  Hepatitis C virus and interferon resistance. , 2000, Microbes and infection.

[27]  Trépo.  Genotype and viral load as prognostic indicators in the treatment of hepatitis C , 2000, Journal of viral hepatitis.

[28]  H. Hauser,et al.  Dynamic redistribution of STAT1 protein in IFN signaling visualized by GFP fusion proteins. , 1999, European journal of biochemistry.

[29]  M. Katze,et al.  Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. , 1997, Virology.

[30]  R. Esteban,et al.  Epidemiology of hepatitis C virus infection. , 1993, Journal of hepatology.

[31]  L. Wang,et al.  Virology Journal , 1966, Nature.